Schuetz Philipp, Daniels Lori B, Kulkarni Prasad, Anker Stefan D, Mueller Beat
Medical University Department, Division of General Internal and Emergency Medicine, Kantonsspital Aarau, Aarau, Switzerland.
UCSD Division of Cardiology, Sulpizio Cardiovascular Center, Mail Code 7411, 9444 Medical Center Drive, La Jolla, CA 92037-7411, USA.
Int J Cardiol. 2016 Nov 15;223:390-397. doi: 10.1016/j.ijcard.2016.08.204. Epub 2016 Aug 11.
Due to its high accuracy for the diagnosis of bacterial infections, the inflammatory biomarker procalcitonin (PCT) is increasingly being used in patients with suspected infection. In patients with infections of the respiratory tract, it allows rapid rule out of bacterial etiology and facilitates decisions pertaining to antibiotic management. A growing body of evidence also supports PCT testing in patients with cardiovascular disorders including, but not limited to, those with shortness of breath, possible heart failure, suspected endocarditis, and acute coronary syndromes. In these clinical situations, PCT may provide diagnostic information on the likelihood of an infectious cause in cardiovascular patients presenting with acute symptoms such as dyspnea. It may also have a prognostic value that correlates with clinical outcome and can potentially guide drug therapy. This narrative review summarizes current concepts and evidence from the published literature on the strengths and limitations of PCT as a biomarker, with a focus on patients with a variety of cardiovascular disorders.
由于炎症生物标志物降钙素原（PCT）对细菌感染的诊断具有高度准确性，它在疑似感染患者中越来越多地被使用。在呼吸道感染患者中，它能快速排除细菌病因，并有助于做出抗生素管理相关决策。越来越多的证据也支持在患有心血管疾病的患者中进行PCT检测，这些疾病包括但不限于呼吸急促、可能的心力衰竭、疑似心内膜炎和急性冠状动脉综合征患者。在这些临床情况下，PCT可能为出现急性症状（如呼吸困难）的心血管疾病患者提供有关感染病因可能性的诊断信息。它也可能具有与临床结果相关的预后价值，并有可能指导药物治疗。这篇叙述性综述总结了已发表文献中关于PCT作为生物标志物的优势和局限性的当前概念和证据，重点关注患有各种心血管疾病的患者。
